• Home
• About Us
  • Management Team
  • Board of Directors
  • Science Advisory Board
  • News
• Product Platform & Pipeline
  • Scientific Foundation
  • Journal Articles
  • ATB-429: Inflammatory Bowel Disease (IBD)
  • ATB-346: Acute and Chronic Joint Pain
  • ATB-284: Irritable Bowel Syndrome (IBS)
• Contact Us
• Intranet Portal

Product Pipeline

Journal Articles

1. Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. BJP 2007; 150: 996-1002
   ( PDF – 161KB)
2. Hydrogen sulfide enhances ulcer healing in rats. FASEB J 2007; 21: 4070-4072
   ( PDF – 267KB)
3. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulphide-releasing diclofenac derivative in the rat. Gastroenterology 2007; 132: 261-271
   ( PDF – 322KB)
4. 5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity. J Pharm Exp Ther 2006; 319: 447-458.
   ( PDF – 862KB)
5. Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharm Exp Ther 2006; 316: 325-335.
   ( PDF – 533KB)
6. GI-sparing anti-inflamatory drugs: A promising future Ann Rev Gastroent & Hepatol 2006; 1: 123-127.
   ( PDF – 154KB)
7. Hydrogen sulphide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 2006; 20: 2118-2120.
   ( PDF – 577KB)
8. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 2006; 131: 259-271.
   ( PDF – 348KB)
9. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugsGastroenterology 2005; 129: 1210-1224.
   ( PDF – 1,247KB)